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Ultrasound biomicroscopy (UBM) is a noninvasive multimodality technique that allows high-resolution imaging in mice. It is
aﬀordable, widely available, and portable. When it is coupled to Doppler ultrasound with color and power Doppler, it can be used
to quantify blood ﬂow and to image microcirculation as well as the response of tumor blood supply to cancer therapy. Target
contrast ultrasound combines ultrasound with novel molecular targeted contrast agent to assess biological processes at molecular
level. UBM is useful to investigate the growth and diﬀerentiation of tumors as well as to detect early molecular expression of
cancer-related biomarkers in vivo and to monitor the eﬀects of cancer therapies. It can be also used to visualize the embryological
development of mice in uterus or to examine their cardiovascular development. The availability of real-time imaging of mice
anatomy allows performing aspiration procedures under ultrasound guidance as well as the microinjection of cells, viruses, or
other agents into precise locations. This paper will describe some basic principles of high-resolution imaging equipment, and the
most important applications in molecular and preclinical imaging in small animal research.
1.Introduction
Mice are widely used as models for studying many human
diseases. The main advantage of research conducted in
small animals is owed to their short life cycle and the
possibility of genetic manipulation. However, most of the
observations in small animals have been based in the past
on surgery and histological postmortem analysis. Few years
ago, research applications of noninvasive imaging methods
such as optical imaging, computed tomography, magnetic
resonance, micro-PET-SPECT, and ultrasound were limited
to larger animals such as dogs and nonhuman primates.
In the recent years, a new ultrasound technology, called
ultrasound biomicroscopy (UBM) was optimized to evaluate
animal models of human disease. UBM is a noninvasive real-
time technique that allows accurate and reliable images of
the heart and other organs in mice [1–3]. Additionally, this
technique is useful to image the fetal mouse [4–6]a n dt o
obtain high-resolution images of mice tumors [7, 8]. The
consistent ultrasound image obtained with the UBM can
be used to visualize and guide injection into target organs
[9, 10], including mouse embryo, to aid in targeted delivery
of drugs and viral particles [7, 11]. UBM allows longitudinal
data acquisition at low cost and noninvasively to investigate
the growth and diﬀerentiation of tumors as well as to
monitor the eﬀects of cancer therapies; therefore, it reduces
the number of animals needed to perform experiments [12].
The basic modalities include B-mode, M-mode, Doppler
mode, 3D reconstruction, power mode, and an ECG-based
Kilo-Herzvisualizationtechnology.Dopplerultrasoundwith
color and power Doppler can be used to quantify blood ﬂow2 Journal of Biomedicine and Biotechnology
and to image microcirculation and the response of a tumor
blood supply to cancer therapy [13]. Recently, the introduc-
tion of ultrasound contrast agents (lipid shell gas-ﬁlled 1–
4 micron sized microbubbles) enhances UBM applications
for detection and characterization of focal lesions. Recently,
the introduction of ultrasound contrast microbubbles that is
targetedtomolecularmarkersexpressedonthevasculatureis
able to image molecular events of disease and could be used
for various applications including quantitative analysis of
molecular biomarkers, perfusion studies, microvasculature
targeting, and gene and drug delivery [7, 11].
Current applications of UBM are the following:
(i) studieson mousedevelopment fromearlyembryonic
period to adulthood,
(ii) in vivo morphological and functional phenotyping
of wild-type, transgenic and mutant mice and other
mouse disease models,
(iii) tumor growth monitoring,
(iv) evaluation of eﬀects of therapeutic interventions,
(v) imaging-guided intervention on mice,
(vi) microinjection for introducing genes or cells into
the developing mouse embryos and follow-up of the
eﬀects,
(vii) ultrasound-guidedcatheterization(veinsorbladder).
This paper describe basic principles of high-resolution
imaging equipment and some applications in molecular and
preclinical imaging in small animal research.
2.UBM Methodology
Human ultrasound scanners are limited to 2–20MHz fre-
quencies, since deep penetration and a axial spatial reso-
lutions of 0.2–1mm is required. UBM uses frequencies of
40–100MHz. Higher frequencies are used to image cellular
structures: the scanning acoustic microscopy (SAM) uses
frequencies of 100MHz-1GHz for the evaluation of thickly
sliced biological tissue or cells [14] and explore the acoustic
properties of single cells with submicrometric resolution.
The choice of ultrasound frequency and the type of
transducer represents a balance between image resolution
and penetration depth.
The high-frequency ultrasound (20–100MHz range) is
used in mice imaging with mechanical sector scanhead
with ﬁxed focus or with electric probes with multiple
focus. These transducers allow high-resolution imaging and
require a mechanical support to perform the necessary
micromovements for mice examinations (Figure 1).
At these frequencies, sound waves are transmitted
through soft tissue relatively to the acoustic impedance of
each tissues. The acoustic impedance of a particular tissue
is the product of sound transmission velocity and tissue
density.Thetransmissionvelocityinmostsofttissueisnearly
uniform at 1540m/s; therefore, the acoustic impedance of
most soft tissue is primarily a function of tissue density.
In the frequency ranging from 20 to 100MHz, only few
studies of attenuation, backscatter, and speed of sound have
been performed. The frequency dependence of attenuation
is strongly dependence on the tissue type. The mechanism
of the diﬀerences between various transducers is not well
understood, but it is known that the concentration of colla-
gen and other structural protein are of primary importance.
In the case of a homogeneous soft tissue, an attenuation
coeﬃcient of 6.5dB/mm can be expected at 60MHz probe
frequency [15]; therefore, a penetration of 6mm would be
expected for a system dynamic range of 80dB.
Backscatter from blood at lower frequencies used in
human diagnostic applications is predominantly dependent
on shear rate due to the formation of red cells aggregates
called “Roleaux.” At frequencies greater than 40MHz, the
backscatter appears less dependent on shear rate, because
the red blood cells begin to act as mirroring reﬂectors.
At higher frequencies, the lumen of the vessel becomes
isoechoic with the surrounding tissue, impeding accurate
boundary discrimination. This natural enhancement of the
blood signal is a beneﬁt for Doppler analysis but at the
expense of B-mode imaging quality.
Resolution is the ability to accurately distinguish two
closely situated structures and becomes a crucial factor when
imaging small targets like mouse organs (the diameter of
an internal carotid artery is 0.2mm, and the left ventricular
posterior wall is approximately 1mm thick [16]. Axial and
lateral resolution improves with increasing frequencies. The
axial resolution is dependent of the pulse spatial length and,
therefore, for ﬁxed cycles number is due to the wavelength.
The lateral resolution is the product of the transducer
diameter, focal length, f-number, and wavelength. Therefore,
the lateral resolution depends from transducers geometry
and wavelength. The f-number equals the depth of returning
echo (focal length) divided by the aperture of the beam
(transducer diameter). It will be best (smallest) if there is
a large aperture of the transducers and short wavelength
(higher frequency).
Utilizing frequency of 40–60MHz and a narrow beam
width, a spatial resolution of 30–50 microns can be obtained.
At these frequencies, the penetration is reduced to 1-2cm.
Hence, increasing axial and lateral resolution by increasing
the frequency limits the depth penetration; however, this
does not aﬀect mice imaging, because most of the target
organs are in the penetration depth range of the high
frequency used.
Temporal resolution is the ability to distinguish two
events in time and is an important factor when imaging mice
hearts that have a heart rate of 400–600 beats/min. At heart
rate of 400 beats/min, a frame rate of 30Hz would result in
only about 4 images for each cardiac cycle. Each image frame
acquires 25% of the cardiac cycle, making the determination
ofthesystolicanddiastolicphaseinaccurate.High-frequency
ultrasound has low imaging frame rates (5–10Hz) with
relatively poor temporal resolution for moving structures.
It is not important when imaging static or slow moving
organs such as liver or xenografts, but it is indispensable
for the evaluation of the heart. The Kilo-Herz visualization
technology use B-mode frame synchronized with ECG trace
that produce a postprocessing imaging equal to a real-time
1,000Hz frame rate.Journal of Biomedicine and Biotechnology 3
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Figure 1: Ultrasound biomicroscopy integrated mechanical support with rail system. The microinjection system for visualization and
guidance of injection and extraction procedures in real time. Ultrasound probe is mounted on a system securing the probe in a stationary
position when the ultrasound scan is in the desired image plane. After anesthesia, the mouse is positioned on a termoregulated pad to
monitor ECG and temperature (with endorectal probe) and ensure mouse comfort during imaging.
TheUBMDopplersystemusingatypicalduplexDoppler
conﬁguration operates at 20–55MHz with a pulse repetition
frequency of 1–20KHz. The transducer is held stationary to
obtainDoppler ﬂowvelocity spectrain realtime forasample
volume located on the B-mode image. The default setting of
Doppler system are pulse repetition frequency (PRF) from
1.0 to 120.0kHz (transmit setting), the wall ﬁlter from 0 to
1000Hz, and the Doppler gain from 1.0 to 10dB (receive
settings).
The Doppler sample volume size changes with the
number of cycle per pulse and insonation frequency from
2.18 to 4.36μL for 20MHz to 0.46 to 0.93μLf o r4 0 M H z
and 8–16 numbers of cycles per pulse. The high-frequency
Doppler system is able to measure velocity from 37cm/sec
(max analyzed velocity at 0◦) to a minimum velocity of
1m m / s e c .T h es y s t e mi sa b l et od e t e c tl o wb l o o dv e l o c i t i e si n
small vessels, and it can calculate blood ﬂow with dedicated
software.
3D UBM imaging allows viewing of the tissue of interest
as a whole organ in diﬀerent orientations. This application
in experimental medicine can be useful in the detection of
xenografttumorsinmiceandinlongitudinalgrowth.Asetof
consecutive 2D image planes of the tumor are acquired then
reconstructed into 3D views for tumor estimation analysis
[17, 18].
An automated method acquires the images, using dedi-
c a t e d2 Dt r a n s d u c e r s .T h ep r o b ei sm o u n t e do nar a i ls y s t e m
equipped with a 3D motor stage.
Based on operator-deﬁned parameters, the 3D motor
stage travels a set distance across the target object in a
series of tiny steps. At each step, the probe takes a two-
dimensional “slice.” Each two-dimensional B-mode image
slice is assembled with the other slices of acquired data
and rendered by the software into a three-dimensional
data set. The digitally stored volume data can be presented
in a three-dimensional view of the acquired data (cube
view), a three single, slidable image slice views (cross view),
“transverse view,” straight-on perspective of the x-y plane
image slice, “sagittal view” and “coronal view” (Figure 2).
3D volumes can be created in 3D-mode or power 3D
mode using parallel or rotational segmentation. For either
method of segmentation, the system can perform a manual
or semiautomated segmentation of the volume. When the
manual segmentation procedure is followed, the operator
draws each contour of the volume. After the semiautomated
segmentation procedure is followed, the system draws two or
more contours automatically.
Vascularization of tissues within the region of interest
can also be assessed using 3D power-Doppler ultrasound
and a percent vascularity value (PV) is provided after the
volume has been created. The PV provides the percentage of
the volume that contains ﬂow detected from power Doppler
mode.
3. Contrast Agent
The most used US contrast agents (both in preclinical
and clinical research) consist of small, stabilized gas-
encapsulated microparticles (<10μm) deﬁned microbubble
contrast agents that we injected into the bloodstream
behave similarly to red blood cells in the microcircu-
lation providing a strongly reﬂective blood/gas interface.
This allows the detection of purely intravascular molecular
targets, whereas intracellular molecular events cannot be4 Journal of Biomedicine and Biotechnology
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Figure 2: Various view of three-dimensional reconstructions of a subcutaneous tumor from two bidimensional successive parallel cross-
section images. (a) Cube view. On the bottom, the segmentational volumetric analysis with a volume estimation of 48.02mm3.( b )S u r f a c e
view. (c) Cross view. (d) Quantitative analysis of tumor growth in a mice model of mammary tumor. The tumor growth curve over time is
showed in the diagram.
imaged. The microbubbles signal is dependent on a number
of factors such as the ﬁlling gas property, for example,
compressibility and solubility, the surrounding medium
properties as viscosity and density, the frequency and power
of ultrasound applied, the bubble size, and shell properties
as elastic modules, thickness, and damping eﬀects. The
behavior of microbubbles depends on the amplitude of
ultrasound to which they are exposed. A very low acoustic
power (mechanical index <0.05–0.1) produces ultrasound
scattering equal to the transmitted frequency. A slightly
higher mechanical index of 0.1–0.3 produces a backscatter
of a variety of frequencies (harmonics, subharmonics, and
ultraharmonics). Higher acoustic pressures (MI > 0.3–0.6)
destroy the microbubbles (Figure 3). This occurrence pro-
duces a high-intensity broadband signal, changes in the
microenvironment, or even shell ballistic events that are
importantfeaturesforbothperfusionimagingandtherapeu-
tic applications as local delivery of drug or genes.
It is possible to target microbubbles to speciﬁc region
of disease. Actually, there are two mechanisms for targeting
the contrast agent: a passive and an active mechanism of
targeting.
The passive targeting mechanism is based on an
unspeciﬁc electrostatic or chemical interaction between the
microbubble shell and the receptors of the endothelial wall
expressed by diseased tissues.
The active targeting mechanism is based on the speciﬁc
binding between shell microbubbles’ ligands and surface
disease antigens. The “active targeting” uses the attachment
of speciﬁc antibodies, such as anti-VEGF for example, to the
surface of microbubbles with streptavidine-biotin interac-
tion (Figure 4). This leads to the accumulation of targeted
contrast agent to speciﬁc sites due to the use of adhesion
ligands including antibodies, peptides, and polysaccharides.
Since the microbubbles remain within the vasculature,
because of their size in the micron range, speciﬁc marker
molecules have to be located in the intravascular space
and on the endothelium to be targeted during pathological
events. Speciﬁc ultrasound imaging protocols are used to
detect retention of targeted microbubbles (Figure 5). After
the bolus injection of the targeted ultrasound contrast agent,Journal of Biomedicine and Biotechnology 5
Figure 3: Behavior of microbubbles depends on the amplitude
of ultrasound to which they are exposed. At very low acoustic
power (mechanical index <0.05–0.1), microbubble oscillates in
relatively symmetrical backscattering at the same frequency of
incident ultrasound. At a slightly higher mechanical index of 0.1–
0.3, the microbubble becomes somewhat oscillates in a nonlinear
manner (nonlinear response), backscattering a variety of frequen-
cies (harmonic). Higher acoustic pressures (MI > 0.3–0.6) destroy
the microbubbles with high-intensity backscatter response.
Figure 4: Schematic representation of active targeting of biotin-
streptavidine bridges. Streptavidine is used for attachment of
biotinylatedligandsontotheshellofultrasoundcontrastmicrobub-
bles. Molecularly targeted microbubbles selective bind to sites of
molecular expression on the endothelium.
it is necessary to wait for 4 to 15 minutes before starting
the contrast-enhanced imaging. This elapsed time allows
retention and clearance of most circulating microbubbles
from the blood pool. Sets of 300 frames (temporal resolution
of 30Hz in a period of 10 seconds) are then captured
to obtain a signal from the tumor tissue background
and contrast agent accumulated in the target site both
retained and freely circulating microbubbles. Therefore,
using destruction-subtraction algorithm the residual cir-
culating contrast signal is measured. After destruction of
m i c r o b u b b l e sb y2t o3s e c o n d so f“ b r e a k ”f r a m e sp e r f o r m e d
with high mechanical index, a new set of 300 frames is
captured to derive the signal only from tumor tissue and
freely circulating microbubbles. The images acquired before
breaking pulses and after breaking pulses are averaged and
digitally subtracted to derive the signal representing only
retained microbubbles. Late imaging modality of single
intravenous injection of contrast media optimizes the signal
coming from retained microbubbles with respect to the one
coming from freely circulating microbubbles, since these
latter are gradually removed from the blood pool. The signal
from freely circulating microbubbles is very low, accounting
for 15% of the contrast signal intensity on initial frames with
the targeted agents. The entire imaging procedure typically
lasts 30 minutes, then data analysis is performed oﬄine,
consistingmainlyofdigitalsubtractionandframealignment,
region-of-interest quantiﬁcation and color map processing.
Many researchers have used microbubbles in small animals
for the detection of molecular markers of inﬂammation,
angiogenesis, and atherosclerosis [19–22].
Ultrasound contrast agents are viable candidates for
gene delivery/therapy. Ultrasound energy determines an
increase of cell membrane permeability (a process known
as sonoporation), which is being increasingly exploited for
its role in drug-delivery applications to transfer therapeutic
agents including genetic material, proteins, plasmid DNA,
and chemotherapeutic agents, directly to the pathological
tissue and organs. The use of US is based on the fact
that the contrast agent can be identiﬁed at the target site
and it can readily be insonated causing ultrasound-induced
rupture of the drug-loaded microbubbles hence achieving
targeted drug release. Most targeted ultrasound contrast
agents are microbubbles, but other vehicles can be used
including acoustically active liposomes and perﬂuorocarbon
emulsions.
Echogenic liposomes can readily be conjugated to anti-
bodies or other adhesion ligands, and thus are readily
conﬁgured as targeted agents. Liposomes, are less than 1mm
in diameter and due to the small diameter, these agents
are not entrapped in the microvasculature of the lung and
have a long circulating time. Additionally, the liquid-like
composition of liposomes makes them more resistant to
pressure and mechanical stress than microbubbles. Another
advantage of liposomes have been used to entrap gas and
drugsforultrasoundcontrolleddrugreleaseandultrasound-
enhanced drug delivery [23]. Echogenic liposomes have
been produced by diﬀerent preparation methods, including
lyophilization, pressurization, and biotin-avidin binding
[24].Additionalbeneﬁtsofliposomesarethatlipidsaresmall
molecular structures and the lipid complexes can be made
smaller by ﬁltering or sonication techniques. Proteins and
delivery agents made of proteins tend to break if they are
manipulated to make them smaller. The diﬀerence lies in the
rigidity of the protein, which has covalent bonds, versus the
lipid, which is composed of small molecules held together by
hydrophobic interactions [25].6 Journal of Biomedicine and Biotechnology
Figure 5: Targeted US of endothelial antigens in vessels of a tumor tissue. On the top of the ﬁgure time/video intensity analysis before and
after high-power destructive pulse and bottom a diagram representation of destructive methodology. Endothelial cells of vessels (orange) of
tumortissuesexpressesspeciﬁcantigens.Afterintravenousadministrationtargetedmicrobubblesﬂoatinvesselsandremainingexclusivelyin
the vascular compartment. Many of them bind to antigens of endothelial cells , whereas others remains in the vessel lumen freely circulating.
After high-power destructive pulse, all microbubbles are destroyed (bound + circulating), following circulating microbubbles that arrive
from outside of scan plane, which remain freely circulating for several seconds. Contrast intensity is the sum of the intensity from tissue,
intensity from microbubbles not bound to receptors (circulating microbubbles), and intensity from microbubbles bound to receptors on
endothelial cells. After digital subtraction of the video intensity calculated on 300 predestruction frames from video intensity calculated on
300 postdestruction frames, resulting video intensity is due only to bound microbubbles.
Perﬂuorocarbon emulsion nanoparticles can be used as
an ultrasound contrast agent. Due to their size (approxi-
mately 250nm) in diameter and composition, these agents
havethesamequalitiesofgasencapsulatedmicrobubblecon-
trast agent and the liposomes [23, 26]. These nanoparticles
avoid lung entrapment. They consist of a lipid encapsulated
p e r ﬂ u o r o c a r b o n ,w h i c hi sal i q u i da tr o o mt e m p e r a t u r e .
The liquid composition makes it resistant to pressure and
mechanical stress. However, due to their small size, their
echogenicity is weak until they are deposited in a layer. This
can be an advantage, as the low free-ﬂoating echogenicity
results in a decreased background noise level. Submicron
particles ﬁlled with liquid perﬂuorocarbon are currently
being studied as a potential ultrasound targeted contrast
agent.
Nanoparticles with directly conjugated tissue factor
antibodydemonstratedacousticenhancementsimilartothat
demonstratedwiththeavidin-biotintargetingapproachwith
the advantage of one step targeting method [27].
Recently, acoustically activated submicron droplets of
liquid perﬂuorocarbon have investigated as a “new class”
of ultrasound contrast agent. In the liquid state, intravas-
cular droplets can extrasavasated within tumors, resulting
a candidate for an extravascular ultrasound contrast agent.Journal of Biomedicine and Biotechnology 7
Table 1: Speciﬁc procedures related to UBM.
Procedures Applications References
Vein injection (jugular vein, femoral vein,
and tail vein)
Contrast agent administration in single bolus
Genes and drugs delivery
[34]
[31]
Blood vessels cannulation Contrast agent administration in repeated bolus [31, 32, 35, 36]
Ultrasound-guided microinjections
V i r a lv e c t o r sa n dg e n ed e l i v e r y [ 37]
Drugs delivery [38]
Guided in utero microinjection [33, 39, 40]
Stem cells therapy [9]
Biopsy Tumor and organ histology
Activation was accomplished by using burst of ultrasound to
vaporize the droplets [28].
Finally, Bekeredjan et al. tested gold-bound microtubules
to provide a backscattering that allowed microtubules to be
potentially useful as an ultrasound contrast agent. Gold-
bound microtubules provide a persistent contrast eﬀect,
suggesting their use as an ultrasonic contrast agent with the
feasibility of antibody conjugation [29].
4. Animals Preparationto UBM Studies
Mice are anesthetized using 1.5%–2% isoﬂurane vaporized
in oxygen with the aid of a precision vaporizer (we used the
vaporizer manufactured by Vetequip Inc., Pleasanton, Calif,
USA) to deliver the appropriate amount of anesthetic, with
constant monitoring of their body temperature (with a rectal
probe) and heart rate. Body temperature is maintained at
35◦C–38◦C using an infrared lamp and a heating pad. Hair
is removed from the area of interest with a chemical hair
remover to obtain a direct contact of the ultrasound gel to
the skin of the animal and to minimize US attenuation. To
provide a coupling medium for the transducer a prewarmed
low-density ultrasound gel is used (we utilize the Aquasonic
100 ultrasound transmission gel, Parker, USA). Using all
these cautions is possible to perform a safe UBM study on
mice without particular regards to the anesthesia duration.
The position of the two-dimensional image plane is obtained
with the ultrasound probe ﬁxed to a rail system that allows
repeatable and precise examinations (Vevo Integrated rail
System II).
5.SpeciﬁcUBM Procedures
Some surgery procedures on mice can be necessary during
studies:tailveininjection,cannulations,andmicroinjections
(Table 1).
Tail vein injection is used to perform contrast UBM
imaging for perfusion studies, for the administration of
drugsorgeneticmaterialscontainedinmicrobubbles.Before
theinjection,avasodilatationisinducedtobetterlocalizethe
lateral tail vein. It is important to avoid injection exceeding
200μL to avoid hypervolaemia and lung edema.
Cannulation has several advantages compared to tail vein
injection: it allows making injections in the jugular vein, and
it is less traumatic for wall vessels and allows controlled and
repeated injections during the same imaging study without
changing the scanning plane.
Cannulation of the jugular vein [30] is an established
method for studying drug pharmacokinetics and eﬀects.
After anesthesia, the skin between the ears and the right-
hand side of the neck of the mouse needs to be shaven
and the skin disinfected. A longitudinal incision of about
15mm is made in the neck of the animal. After careful
removal of the connective tissue surrounding the jugular
vein, the cannula, ﬁlled with heparin solution (750 units/mL
inwater),isinsertedintotheveininthecaudaldirection.The
cannula is ﬁxed to the jugular vein by ligation. Finally, the
incision in the neck of the animal is closed using 5/0 Ethilon
silksutureandametalspringisﬁrmlyattachedtothestitches
(Figure 6(a)).
Cannulation of the lateral tail veins [31, 32] can also be
performed in the mouse to inject contrast ultrasound agent.
Animals are immobilized by taping the tail to an 18cm ×
7cm plexiglass rectangle and by fastening a restraint tube
(125mL half-Nalgene bottle) using rubber bands. The tail
is then washed and immersed in warm water (42◦C) for
approximately 45 seconds to dilate the tail veins. After this,
the tail is cleaned and wiped with ethanol. A 27-gauge needle
connected by PE 10 tubing to a 1mL saline-ﬁlled syringe is
inserted into the right lateral vein approximately 2cm from
thebodyanditsintravascularpositionconﬁrmedbydrawing
blood (Figure 6(b)). The needle is then removed, and a
saline-heparin-(SH;150IU/mL)ﬁlledcatheterisintroduced
through the access site. Proper position of the catheter in the
vein is veriﬁed by the observation of blood backﬂow. The
catheter is then secured to the tail using cyanoacrylate glue
(we use Histoacryl, B Braun, Am Aesculap-Platz, Germany)
at the point of insertion.
UBM-guided injections, such as targeted injections of
retroviruses, cells, or genetic materials in mouse embryos,
can be done manually [10] or by mechanical guide [33]
and can be performed transcutaneously or with surgical
exposure of the target organ. Injections can be performed
with 50μL Hamilton syringe and a 30 gauge needle [10]o r
with microinjector units and capillary glass needle that can
inject very small volume (about 10nL).
6. In Utero Microinjections
In utero ultrasound-guided microinjection of mouse
embryos has proven a valuable tool for exploring the8 Journal of Biomedicine and Biotechnology
(a) (b)
Figure 6: Cannulation of jugular and tail veins. The anesthetized mouse is immobilized by taping its harms on a termoregulated pad. A
side of the neck or the tail of the mouse are disinfected. A 27-gauge needle connected by polyethylene tubing (PE10) to a 1mL saline-ﬁlled
cannulaisinsertedintothejugularveinorinthelateraltailveinapproximately2cmfromthebody.Thecannula,ﬁlledwithheparinsolution
(750 units/mL in water), is inserted into the vein in caudal direction and ﬁxed to the vein with cyanoacrylate glue (Histoacryl, B Braun, Am
Aesculap-Platz, Germany). The proof of the correct position of the needle is given by blood visualization in the cannula. (a) Cannulation of
jugular vein. (b) Cannulation of lateral tail vein.
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Figure 7: In utero microinjection: laparoscopy along the linea alba. The uterine horns are gently exteriorized to record implantation sites
and simply positioned on sterile gauze and covered with sterile acoustic gel (a). A 40Mhz probe is used to image in real time the embryos,
and the microinjection is performed by an automatic microinjector equipped with a capillary glass needle. The needle is advanced with
the use a micromanipulator under echo guidance until the needle tip is in the desired location (b). UBM images of a capillary glass needle
advanced under echo guidance until the needle tip is in the amnions (c).Journal of Biomedicine and Biotechnology 9
developmental consequences of altering gene expression
using viral vectors and for injecting cells to study cell
lineage or migration and to validate gene therapies.
Pregnant females need to be monitored during anesthesia.
Physiological parameters such as heart rate, respiratory
frequency, and temperature are useful to assess anesthetic
depth during the procedure and the maternal-fetal well-
being. Microinjection procedure contemplate a laparoscopy
along the linea alba after skin disinfection with 70% ethanol.
The mouse is mounted on the stage of a rail system, which
permits the operator to readily adjust the position of
the mouse while maintaining the microinjection pipette
within the transducer-imaging plane. The uterine horns are
gently exteriorized to record implantation sites and simply
positioned on sterile gauze and covered with sterile acoustic
gel (Figure 7(a)).
A 40Mhz probe is used to image in real time the
embryos,andmicroinjectionisperformedwithanautomatic
microinjector equipped with a capillary glass needle. The
needle is advanced with the use a micromanipulator under
echo guidance until the needle tip is in the desired location
(Figure 7(b)). In this way, the procedure is less traumatic
for the embryos, and a very small amounts of material can
be injected, signiﬁcantly reducing the risk of embryonic
death. After microinjecting all sites, the gel is removed with
a squeeze bottle containing sterile PBS, and embryos are
placed back into the body cavity. The maternal abdomen is
then closed using a 8–0 silk suture using a continuous stitch
up, anesthesia is discontinued, and the mouse is placed in a
heatedrecoverychamber.UBMisperformedinthefollowing
two days to test the fetuses’ health status.
Commonly, microinjection is performed at embryonic
day 9.5 (E9.5) or greater, but recently, with advances in
technology, it has been reported the possibility to accurately
target speciﬁc regions of the embryos under high-resolution
ultrasound guidance at E6.5 to E7.5 of gestation [33].
7. Applications
7.1. Oncology. High-Frequency ultrasound represents a sig-
niﬁcantadvancementinthephenotypicassessmentofmouse
cancer models. Tumor size can be quantiﬁed by 2D and
3D ultrasound imaging in several xenograft models. Pezold
et al. [41] demonstrated in a murine orthotopic oral
cavity tumor model that tumor dimensions acquired with
ultrasound measurements were not signiﬁcantly diﬀerent
comparedtohistologicalmeasurement[42].Moreover,high-
frequency ultrasound allows noninvasive longitudinal assays
[17]; UBM detects small tumor nodules in early stage with
lower limit of detection at approximately 0.4mm in volume
(Figure 8). In a model of thyroid cancer UBM detected
the presence of malignant thyroid nodules quite early, long
before they were palpable, and UBM results were compared
with histological ﬁndings [2].
In a model of human mammary cancer, 3D was used
to monitor tumor growth every week and to detect tumor
response after therapy, showing a better correlation with
postmortem ﬁndings in comparison to other imaging tech-
nique like bioluminescence and positron emission tomogra-
phy [43] (Figure 9).
Recently, Banihashemi et al. [44] demonstrated that
UBM is able to detect apoptotic cell death in a preclinical
tumor model of melanoma after treatment with photody-
namic therapy in models of bladder and colorectal cancer.
Power Doppler ultrasound captures ﬂow-dependent
signals in blood vessels and can be used to assess neo-
angiogenesis. However, its sensitivity is limited to ves-
sels larger than capillaries. Xuan et al. [13] reported the
ﬁrst application of high-frequency three-dimensional power
Doppler ultrasound imaging in a genetically engineered
mouse prostate cancer model. Tumor vascularity was quan-
tiﬁed in power Doppler images by computing the color pixel
density for the entire tumor and the peripheral part of the
prostate tumor. The vascular architecture at diﬀerent stages
of tumor growth was detected comparing 3D power Doppler
with contrast-enhanced micro-CT. Comparisons suggested
that the smallest vessels reliably detected by power Doppler
were from 100 to 150μm diameter. Contrast agents revealed
allperfusedvesselsbyassessingstimulatedacousticemissions
from microbubbles. Angiogenesis can be enhanced in neo-
plastic tissues by several mechanisms such as overexpression
of angiogenetic factors or mobilization of angiogenetic
proteins in the extracellular matrix [45], and the amount of
new blood vessel growth is correlated with poor prognosis in
several tumor types [46]. Therefore, there is a great interest
in the development of antiangiogenetic drugs such as anti-
VEGF treatments and of imaging techniques that could be
helpful in quantifying tumor vasculature and the VEGF
expression.
More recently, Willman et al. [35] demonstrated that
angiogenesis is detected in angiosarcoma and malignant
glioma in mice using microbubbles labeled with mono-
clonal antibodies against murine VEGF-R2. A dual-targeted
contrast-enhanced US directed at both VEGF-R2 and
alpha(v)beta(3) integrin improves in vivo visualization of
tumor angiogenesis in a human ovarian cancer xenograft
tumor model in mice.
A major challenge for tumor therapy is to obtain eﬀects
directly into an aﬀected tissue of nucleic acids delivered in
systemic circulation. Intravenous injections of a replication
incompetent adenovirus with a cytokine displaying can-
cer selective-apoptosis profoundly inhibits prostate cancer
growthinanimalsinwhichthetumorwasinsonatedincom-
parison with the control groups injected with adenovirus but
not insonated. These ﬁndings demonstrate the utility and
the potential therapeutic applications of novel microbubbles
guided gene therapy technology [7].
7.2. Cardiology. UBM provide an opportunity to character-
ize anatomy and physiology of heart and great vessels in a
safe, reliable, and noninvasive modality in adult mice.
2D and 3D imaging have been used to evaluate cardiac
structure and valves morphology and function in mice
[1, 47, 48], to calculate cardiac function parameters such
as stroke volume, cardiac output, ejection fraction, and
fractional shortening, and to assess global left ventricular
function and LV mass [8, 47–49] in normal and in models10 Journal of Biomedicine and Biotechnology
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Figure 8: (a) UBM microimaging of thyroid in living mice performed with a 35MHz probe in a genetically engineered mice model of
thyroid disease (TRK). The ﬁgure shows an enlarged left lobe with hypoechoic nodule (arrows). (b) Histopathology analysis shows a thyroid
adenoma. From Mancini et al. Endocrinology [2].
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Figure 9: Multimodality imaging of the lesion: human mammary tumor cells were implanted in the mammary fat pad of an athymic nude
mice, 6 weeks old. There is a good correspondence between the morphology and the size of the tumor detected by UBM and necroscopic
ﬁndings. (a) Bioluminescence of the tumor. (b) 18F-ﬂourothymidine total body PET, tumor uptake is evident (arrow). (c) UBM with
measurements of neoplasia. (d) Post mortem dimension of the explanted tumor.
of cardiovascular diseases [50–54]. Pharmacological eﬀects
of various agents tested in mouse models have also been
evaluated with echocardiography [55, 56].
Small heart size hampers accurate injection into the left
ventricular (LV) wall and require surgical visualization of
the heart, but that, however, do not prevent unintentional
injection into the LV cavity. High-resolution echocardiog-
raphy is able to guide cardiac injections accurately into the
myocardial wall of mice with closet chest. This system was
successful to target the injection of labeled cells into speciﬁc
cardiac regions such as myocardium adjacent to ischemic
area in a mouse myocardial infarction model or to treat
ischemic myocardium implanting bone marrow cells and to
guide left ventricular catheterization [9, 10].
Microbubbles have been applied mainly as blood pool
agents to enhance the echogenicity of the cardiac cham-
bers during echocardiography for better delineation of the
myocardial borders and for perfusion assessment of the
myocardium [57].
Using 2D B-mode imaging, fetal heart development can
be detected in mice as early as embryonic day 8.5, when the
linear heart tube begins to beat. On day 9.5, the U-shaped
heart tube is clearly visible, and Doppler blood velocity
waveforms can be recorded separately from the inﬂow and
outﬂowregionsofthehearttube(Figure10(a)).Onday11.5,
it is possible to detect the process of division of the outﬂow
tract into the ascending aorta and main pulmonary artery
(Figure10(b)).AtE12.5,theseparationoftheaortaandmain
pulmonary artery appears complete, but the interventricular
septum is visibly incomplete, and ﬂow streams from both
ventricles can be seen entering the aorta (Figure 10(c)). At
day 13.5, the embryonic ventricles are fully separated by a
septum, the atrioventricular valves are visible, and the heart
has a mature fetal form (Figure 10(d)). After day 15.5, the
heartchambersbegintodarkenintheultrasoundimage,and
the ventricular wall, endocardium, and septum are easier to
bediscerned(Figure10(e)).Theimprovedcontrastseenafter
day 15.5 means that ventricular chamber dimensions and
wall thickness measurements become feasible [5, 58]. Fetal
blood is echodense at UBM frequencies, due to nucleated
erythroblasts, and this may facilitate assessment of major
vascular development.Journal of Biomedicine and Biotechnology 11
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Figure 10: (a) E9.5: heart tube and doppler spectral trace of ventricular inﬂow and outﬂow at 9.5 gestational age. (b) E11.5: doppler
spectral trace of ascending aorta outﬂow at 11.5 gestational age. (c) E12.5: bidimensional image of atrio-ventricular chambers (a–V)
interventricular septum (IVS); and doppler spectral trace of ascending aorta outﬂow at 12.5 gestational age. (d) E13.5: bidimensional image
of atrioventricular chambers, interventricular septum, and left ventricle wall (LV wall); doppler spectral trace of ventricular inﬂow and
outﬂow at 13.5 gestational age. The atrial wave (A-wave) was dominant. The rapid ventricular ﬁlling (E-wave) is a measure of ventricular
compliance. (e) E15.5: bidimensional image of ventricular chambers, interventricular septum, and left ventricle wall in telesystolic and
telediastolic fase of heart cycle in a 15.5 days mouse embryo.
Noninvasive transthoracic echocardiography in newborn
C57BL mice has been shown to deﬁne normal cardiac and
great vessel anatomic measurements [59].
T h em o u s eh a sb e c o m eap o w e r f u lt o o lf o rs t u d y i n g
genetic models of cardiac development and congenital
heart disease and echocardiography is an ideal method for
detecting and studying congenital malformations in living
fetus, as it allows early recognition of abnormalities and
the progression of disease can be followed in utero with
longitudinal studies [5, 48, 59, 60].
7.3. Developmental Biology. In utero imaging of live mouse
embryos allows studies of early embryonic developmental
stages, embryonic neural tubes and heart development, and
the eﬀects of mutant phenotypes during embryogenesis.
UBMresolutionissuﬃcienttovisualizesmallanatomical
structures, especially at embryonic and early postnatal stages
[61] and to study the morphology of various organ systems
throughout development.
The feasibility of UBM for in vivo morphometric quan-
tiﬁcationofembryonicgrowthandforestimatinggestational
age and embryonic body weight in utero as discussed
elsewhere [62, 63].
At the earlier stage (E11.5), major features of the embryo
can be identiﬁed, including amniotic membrane and cavity,
yolk sac, placenta, umbilical vessels, and heart and brain
ventricles. At later stages (>E13.5), brain, mouth, eyes, lungs,
heart chambers, liver, kidneys, chest wall, spine, limbs, and
tail are also clearly visualized.
Inthesemi-invasiveapproach,asmallincisionismadein
theabdominalwall,andoneortwoembryosareexteriorized.
It has the advantage to exclude the maternal abdominal wall,
and intra-abdominal content to provide a better resolution
of embryonic structures.
Doppler ﬂow in the developing brain has also been
obtained [59, 64]. Investigations about eyes limbs and spine
and skin oculodentodigital dysplasias in mouse embryos
have also been reported using this technology [39, 40, 65].
7.4. Ocular Applications. UBM is a good tool for imaging the
anterior ocular segment anatomy and pathology, including
the cornea, anterior chamber, iris, ciliary body, and lens12 Journal of Biomedicine and Biotechnology
[31,32,34,36,66–69].ThroughoutdevelopmentuntilE18.5,
anterior segment structures appear compressed, revealing
little structural detail or diﬀerentiation from surrounding
tissues. It is possible to perform several quantitative analysis:
measurements of the corneal thickness, of the anterior
chamber depth, of the trabecular-iris angle, and of the
iridozonular distance. It is, thus, applicable for diagnostic
imaging of corneal diseases, glaucoma, cysts, and tumors.
Imaging of posterior structures of the eye, and in particular,
the retina and the optical nerve can also be obtained.
Normal embryonic development of the mouse eye can
be studied by ultrasound biomicroscopy with a focus on
the formation of the retina, lens, and cornea. The earliest
stages of development that can be successfully imaged are at
approximately E8.5, coinciding with the appearance of the
optic placode and vesicle. At this point, the morphogenesis
of the eye is very primitive, and features of the developing
tissues are close to the resolution limit of the scanner.
Subsequent development of the lens vesicle, retina, cornea,
vitreous, and conjunctiva can be observed up to the birth of
the mouse. No evidence of ﬂow has yet been observed in the
developing prenatal mouse eye.
8. Conclusions
Advantages of ultrasound imaging over other imaging tech-
niquesthatuseionizingradiation(e.g.,PET,SPECT,andCT)
is that it less invasive, does not require specialized ancillary
equipments, is safer for the animals and the operators, and,
ﬁnally, is a low-cost technology.
However, ultrasound imaging has also some limitations
as a research tool. In fact, it requires the knowledge and
expertise of a well-trained sonographer to obtain accurate
and repeatable images and is limited by bone- and gas-ﬁlled
structures; therefore, ultrasound is not routinely used in
brain, spinal cord, and lung imaging. The development of
novel targeted contrast agents will foster future applications
to study the molecular basis of animal models. UBM provide
a noninvasive imaging of both embryos and adult mice
anatomy and pathology. It is an excellent tool for cancer
research and cardiovascular investigations to analyze ocular
and abdominal structures and embryos development.
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